


Product description

<p>Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.</p>	
<p>Nivolumab sequence</p>	<p>Heavy chain EVQLVESGGGLVQPGGSLRLSCAASGYFTFTNYGMNWVRQAPGKGLEWVGVWINTYTGPEY AADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYGSSHWYFDVWGQGLT VSSASTKGPSVFLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSVHTFPAVL QSSGLYSLSSVTVPSSSLGTQTYICNVNHHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEL LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK</p> <p>Light chain DIQMTQSPSSLSASVGRVTITCSASQDISNYLNWYQQKPKGKAPKVLIVFTSSLSHGVP RFGSGSGTDFLTITSLQPEDFATYYCQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPP SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKSTYLSLSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</p>
<p>Purity</p>	<p>Greater than 95% as determined by SDS-PAGE analysis</p>
<p>Isotope incorporation</p>	<p>Arginine: $^{13}\text{C}_6$, $^{15}\text{N}_4$, >99% Lysine: $^{13}\text{C}_6$, $^{15}\text{N}_2$, >99%</p>
<p>Form and reconstitution</p>	<p>The product is supplied as a lyophilized powder. Store below -20°C upon receipt.</p> <p>Reconstitute by adding ultrapure water and let 15-20 min at room temperature to optimize reconstitution, vortex and centrifuge. After reconstitution, protein can be kept at 4°C for a few weeks.</p>



Packaging

Protein	Description	Storage solution	Total quantity	Estimated purity
Beva-13C15N	Stable isotope labelled standard for quantification of Bevacizumab in biological samples using LC-MS	10 mM PBS 60 mM trehalose 0.01% Polysorbate 20	10 µg	> 95%

This product is for research use only and is not intended for diagnostic or therapeutic use. PROMISE Advanced Proteomics shall not be held responsible for any damages resulting from the use of this product.

Bevacizumab labelled standard



Legal	This product is licensed under U.S. Patent No. 7,396,688 and foreign counterparts from E. I. du Pont de Nemours and Company. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product for research and development only. Information about licenses for other uses is available from: E. I. du Pont de Nemours and Company; Attn: Associate Director, Commercial Development; DuPont Experimental Station E268; 200 Powdermill Rd.; Wilmington, DE 19803; 1-877-881-9787 (voice), 1-302-695-1437 (fax), licensing@dupont.com .
--------------	--

PROMISE Advanced Proteomics

Zone Minatec Entreprises – BHT 52A
7, parvis Louis Néel – CS20050
38040 Grenoble Cedex 9 – France

Tel : +33 (0) 4.38.02.36.61
Fax : +33 (0) 4.76.96.10.38
contact@promise-proteomics.com
www.promise-proteomics.com/

SAFETY DATASHEET

Issuing Date : 2017/06/27

Revision Date :

Version: 1

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

Product identifier : Bevacizumab-C13N15

Relevant identified uses of the substance or mixture and uses advised against

This product is for research use only.

This product is not intended for therapeutic use. It should not be administered to humans or animals.

Details of the supplier of the safety data sheet

PROMISE Advanced Proteomics

7 parvis Louis Néel, CS20050, Bat52A

38040 Grenoble

FRANCE:

Tel: +33.4.38.02.36.50

Fax: +33.4.38.02.10.38

Email: contact@promise-proteomics.com

Emergency telephone number: +0033.4.38.02.36.50 (8.00am-17.00pm)

Email: reactovigilance@promise-proteomics.com

2. HAZARDS IDENTIFICATION

Classification of the substance

Non-Toxic and Non-Infectious

Label elements

Other information

The preparations do not contain any animal derived additives.

The materials do not come from a facility where work with exotic viruses affecting livestock and avian species is conducted.

The materials are recombinant but contain no genes and express no products of exotic livestock or poultry disease agents.

3. COMPOSITION/INFORMATION OF INGREDIENTS

Stable isotopically labelled Bevacizumab antibody

4. FIRST AID MEASURES

Description of first aid measures

- Eye contact: Immediately flush with plenty of water. After initial flushing, remove any contact lenses and continue flushing for at least 15 minutes.
- Skin contact: Wash off immediately with soap and plenty of water while removing all contaminated clothes and shoes.

- Ingestion: Clean mouth with water. Drink plenty of water.
- Inhalation: Move to fresh air.

Most important symptoms and effects, both acute and delayed

No information available

Indication of any immediate medical attention and special treatment needed

Treat symptomatically

5. FIRE-FIGHTING MEASURES

Extinguishing media

Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Special hazards arising from the substance or mixture

None in particular.

Advice for fire-fighters

Special protective equipment for fire-fighters As in any fire, wear self-contained breathing apparatus and full protective gear.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures

Ensure adequate ventilation.

Environmental precautions

Prevent further leakage or spillage if safe to do so.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material (e.g. sand, silica gel, acid binder, universal binder, sawdust).

7. HANDLING AND STORAGE

Precautions of safe handling

Ensure adequate ventilation.

Conditions of safe storage, including any incompatibilities

Keep container tightly closed in a dry and well-ventilated place.

Specific end uses

No information available.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Control parameters:

Exposure limits: National occupational exposure limits

Derived No Effect Level: No information available

Predicted No Effect Concentration: No information available

Exposure controls:

Engineering measures Ensure adequate ventilation, especially in confined areas.

Personal protective equipment

Eye protection Tightly fitting safety goggles.

Hand protection Protective gloves.
Skin and body protection Long sleeved clothing.
Respiratory protection No special protective equipment required.
Thermal hazards No information available

Hygiene measures:

Handle in accordance with good industrial hygiene and safety practice.

Environmental exposure controls : No information available.

9. PHYSICAL AND CHEMICAL PROPERTIES

Information on basic physical and chemical properties

Physical State @20°C: No information available

Odor: No information available

Appearance: no information available

pH: No information available

Melting/freezing point: No information available

Boiling point/boiling range: No information available

Flash point: No information available

Evaporation rate: No information available

Flammability (solid,gas): No information available

Vapor pressure: No information available

Vapor density: No information available

Relative density: No information available

Water solubility: No information available

Solubility in other solvents: No information available

Partition coefficient : n-octanol/water: No information available

Autoignition temperature: No information available

Decomposition temperature: No information available

Viscosity, kinematic: No information available

Explosive properties: No information available

VOC content (%): No information available

10. STABILITY AND REACTIVITY

Reactivity: No information available

Chemical stability: Stable under normal conditions

Precautional Statements: None under normal processing

Conditions to avoid: Heat, flames and sparks.

Incompatible materials: None in particular

Hazardous decomposition products: None under normal conditions.

11. TOXICOLOGICAL INFORMATION

Information on toxicological effects

Product information: No data available

Inhalation: No data available

Eye contact: No data available

Skin contact: No data available

Ingestion: No data available

Chronic toxicity

Corrosivity: No information available

Sensitization: No information available

Neurological effects: No information available

Reproductive toxicity: No information available

Mutagenic effects: No information available

Target Organ effects: No information available

12. ECOLOGICAL INFORMATION

Toxicity: As supplied, the preparation is not expected to present significant adverse environmental effects.

Persistence and degradability: No information available

Bioaccumulative potential: No information available

Mobility in soil: No information available

Results of PBT and vPvB assessment: No information available

Other adverse effects: No information available

13. DISPOSAL CONSIDERATIONS

Waste from residues/unused products: Dispose of in accordance with local regulations.

Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.

14. TRANSPORT INFORMATION

15. REGULATORY INFORMATION

16. OTHER INFORMATION

Issue date: 2017/06/27

Revision Note:

This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006

Disclaimer:

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty of quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or any in process, unless specified in the text.